secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2025-01-17T23:59:59+00:00
Accession:  0000950170-25-006495
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Pharmaceuticals CCO Christopher Von Seggern departs; consulting agreement through May 2025
--------------------------------------------------------------------------------

- Christopher Von Seggern ceased as Chief Commercial Officer on January 17, 2025.
- Separation Agreement provides severance per 2020 offer letter and 2024 annual bonus.
- Consulting Agreement through May 1, 2025; equity awards continue vesting until then.
- No replacement named for the CCO role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017025006495/0000950170-25-006495-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017025006495/xene-20250117.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-006495

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer